» Articles » PMID: 39356625

Resistance Management for Cancer: Lessons from Farmers

Abstract

One of the main reasons we have not been able to cure cancers is that treatments select for drug-resistant cells. Pest managers face similar challenges with pesticides selecting for pesticide-resistant insects, resulting in similar mechanisms of resistance. Pest managers have developed 10 principles that could be translated to controlling cancers: (i) prevent onset, (ii) monitor continuously, (iii) identify thresholds below which there will be no intervention, (iv) change interventions in response to burden, (v) preferentially select nonchemical control methods, (vi) use target-specific drugs, (vii) use the lowest effective dose, (viii) reduce cross-resistance, (ix) evaluate success based on long-term management, and (x) forecast growth and response. These principles are general to all cancers and cancer drugs and so could be employed broadly to improve oncology. Here, we review the parallel difficulties in controlling drug resistance in pests and cancer cells. We show how the principles of resistance management in pests might be applied to cancer. Integrated pest management inspired the development of adaptive therapy in oncology to increase progression-free survival and quality of life in patients with cancers where cures are unlikely. These pest management principles have the potential to inform clinical trial design.

Citing Articles

Testing Adaptive Therapy Protocols Using Gemcitabine and Capecitabine in a Preclinical Model of Endocrine-Resistant Breast Cancer.

Seyedi S, Teo R, Foster L, Saha D, Mina L, Northfelt D Cancers (Basel). 2024; 16(2).

PMID: 38254748 PMC: 10813385. DOI: 10.3390/cancers16020257.

References
1.
Pessoa L, Heringer M, Ferrer V . ctDNA as a cancer biomarker: A broad overview. Crit Rev Oncol Hematol. 2020; 155:103109. DOI: 10.1016/j.critrevonc.2020.103109. View

2.
Hughes D, Andersson D . Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet. 2015; 16(8):459-71. DOI: 10.1038/nrg3922. View

3.
Giraudo M, Califano J, Hilliou F, Tran T, Taquet N, Feyereisen R . Effects of hormone agonists on Sf9 cells, proliferation and cell cycle arrest. PLoS One. 2011; 6(10):e25708. PMC: 3185036. DOI: 10.1371/journal.pone.0025708. View

4.
Chen K, Lou F, Yang F, Zhang J, Ye H, Chen W . Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing. Sci Rep. 2016; 6:31985. PMC: 4995492. DOI: 10.1038/srep31985. View

5.
Seidman A, Fornier M, Esteva F, Tan L, Kaptain S, Bach A . Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001; 19(10):2587-95. DOI: 10.1200/JCO.2001.19.10.2587. View